Idiopathic hypereosinophilic syndrome presenting acute abdomen

Internal Medicine

Volumn 46, Issue 10, 2007, Pages 675-678

  Kobayashi, Makoto ^a   Komatsu, Naoki ^a   Kuwayama, Yoshio ^a   Bandobashi, Kentaro ^a   Kubota, Tetsuya ^a   Uemura, Yoshiki ^a   Taguchi, Hirokuni ^a  

^a KOCHI UNIVERSITY   (Japan)

Author keywords

Eosinophilic pneumonia; FIP1L1 PDGFRA fusion gene; Mesenteric artery; Multiple thromboses

Indexed keywords

ACETYLSALICYLIC ACID; BAYASPIRIN; PREDNISOLONE; UNCLASSIFIED DRUG; WARFARIN;

ACUTE ABDOMEN; ADULT; ANTICOAGULANT THERAPY; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; COLOSTOMY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG PULSE THERAPY; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERTHERMIA; INTESTINE PERFORATION; LAPAROTOMY; LIMB AMPUTATION; LOEFFLER PNEUMONIA; MALE; MESENTERIC ARTERY OCCLUSION; THROMBOSIS;

ABDOMEN, ACUTE; ADULT; GLUCOCORTICOIDS; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; MESENTERIC ARTERIES; METHYLPREDNISOLONE; THROMBOSIS;

EID: 34249825778     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.6309     Document Type: Article

References (22)

1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophillic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54: 1-27, 1975.
2. Brito-Babapulle F. The eosinophilias including the idiopathic hypereosinophilic syndrome. Br J Haematol 121: 203-223, 2003.
3. Godlib J, Cools J, Malone III JM, Schrier SL, Gilliland G, Coutre SE. The FIP1L1-PDGFRa fusion tyrosine kinase in hyperosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103: 2879-2891, 2004.
4. Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 19: 792-798, 2005.
5. Muller AMS, Martens UW, Hofmann SC, Bruckner-Tuderman L, Martelsmann R, Lubbert M. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Ann Hematol 85: 1-16, 2006.
6. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophihc syndrome. N Engl J Med 348: 1201-1214, 2003.
7. Gleich GJ, Leiferman KM. The hypereosinophilic syndromes: still more heterogeneity. Curr Opin Immunol 17: 679-684, 2005.
8. Cools J. The hypereosinophilic syndrome: idiopathic or not, that is the question. Haematologica 90: 582-584, 2005.
9. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 133: 468-492, 2006.
10. Cave H, Guidal C, Rohrlich P, et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukerma by polymerase chain reaction study of δ and γ T-cell receptor genes. Blood 83: 1892-1902, 1994.
11. Simon HU, Plotz GS, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341: 1112-1120, 1999.
12. Johnston AM, Woodcock BE. Acute aortic thrombosis despite anticoagulant therapy in idiopathic hypereosinophilic syndrome. J R Soc Med 91: 492-493, 1998.
13. Ferguson GT, Starkebaum G. Thromboangitis obliterans associated with idiopathic hypereosinophilia. Arch Intern Med 145: 1726-1728, 1985.
14. Ponsky TA, Brody F, Giordano J, Garcia R, Kardon D, Schwartz A. Brachial artery occlusion secondary to hypereosinophilic syndrome. J Vasc Surg 42: 796-799, 2005.
15. Spry CJ. The hypereosinophilic syndrome: clinical features, laboratory findings and treatment. Allergy 37: 539-551, 1982.
16. Keogh KA, Specks U. Churg-Strauss Syndrome. Semin Respir Crit Care Med 27: 148-157, 2006.
17. Slungaad A, Vercelloti GM, Tran T, Gleich GJ, Key NS. Eosinophil cationic granule proteins impair thrombomodulin function: A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest 91: 1721-1730, 1993.
18. Aractingi JF, Janin A, Zini JM, et al. Specific mucosal erosions in hypereosinophilic syndrome. Evidence for eosinophil protein deposition. Arch Dermatol 132: 535-541, 1996.
19. Plotz SG, Simon HU, Darsow U, et al. Use of an anti-interleukin 5 antibody in the hypereosinophilic syndrome with eosmophilic dermatitis. N Engl J Med 349: 2334-2339, 2003.
20. Kilon AD, Law MA, Noel P, Haverty TP, Nutman TB. Safety and efficacy of the monoclonal anti-interleukin 5 antibody, SCH55700, in the treatment of patients with the hypereosinophilic syndrome. Blood 103: 2939-2941, 2004.
21. Ueno NT, Anagnostopoulos A, Rondon G, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 119: 131-134, 2002.
22. Kilon AD, Bochner BS, Gleich GJ, et al. The Hypereosinophilic Syndromes Working Group. Approaches to the treatment of hypereosinophilic syndrome: A workshop summary report. J Allergy Clin Immunol 117: 1292-1302, 2006.